Antiplatelet effects of the addition of acetylsalicylic acid 40 mg daily to ticlopidine in human healthy volunteers

Clinical and Applied Thrombosis/Hemostasis

Volumn 3, Issue 4, 1997, Pages 245-250

  Lecompte, Thomas P ^a   Lecrubier, Chantal ^a   Bouloux, Cyril ^b   Horellou, Marie Hélène ^a   Galleyrand, Jacques ^b   Maffrand, Jean Pierre ^b   Samama, Meyer M ^a  

^a HÔTEL DIEU   (France)

^b SANOFI   (France)

Author keywords

Aspirin; Bleeding time; Drug combination; Platelet aggregation; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; COLLAGEN; PLACEBO; THROMBOXANE; TICLOPIDINE;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG MIXTURE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0031409872     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969700300405     Document Type: Article

References (40)

1. Antiplatelet trialists' collaboration: Collaborative overview of randomized trials of antiplatelet therapy: I. prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81.
2. Reilly IAG, FitzGerald GA. Aspirin in cardiovascular disease. Drugs 1988;35:154.
3. Lecrubier C, Conard J, Samama M, Bousser MG. Essai randomisé d'un nouvel agent antiagrégant: La Ticlopidine. Thérapie 1977;32: 189.
4. Nunn B, Lindsay R. Effect of ticlopidine on human platelet responsiveness ex vivo: Comparison with aspirin. Thromb Res 1980; 18:807.
5. Conard J, Lecrubier C, Scarabin PY, Horellou MH, Samama M, Bousser MG. Effects of long term administration of ticlopidine on platelet function and hemostatic variables. Thromb Res 1980;20: 143.
6. Bruno JJ. The mechanisms of action of ticlopidine. Thromb Res 1983;(suppl 4):59.
7. Di Minno G, Cerbone AM, Mattioli PL, Turco S, lovine C, Mancini M. Functionally thrombasthenic state in normal platelets, following the administration of ticlopidine. J Clin Invest 1985;75: 328.
8. Gachet C, Stierlé A, Cazenave JP, Ohlmann P, Lanza F, Bouloux C, Maffrand JP. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol 1990;40:229.
9. Gachet C, Cazenave JP, Ohlmann P, Bouloux C, Defreyn G, Driot F, Maffrand JP. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Biochem Pharmacol 1990;40:2683.
10. Hardisty RM, Powling MJ, Nokes TJC. The action of ticlopidine on human platelets. Studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost 1990; 64:150.
11. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988;77:1213.
12. Hears M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989;79:657.
13. Runge MS. Prevention of thrombosis and rethrombosis. New approaches. Circulation 1990;82:655.
14. Patrono C, Ciabattoni G, Pinca E, et al. Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17:317.
15. Weksler BB, Kent JL, Rudolph D, Scherer PB, Levy DE. Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia. Stroke 1985;16:5.
16. De Caterina R, Boem A, Gazzetti P, Sicari R, Giannessi D, Ciabattoni G, Patrono C. Long-term maintenance of thromboxane inhibition by two different aspirin regimens in patients with unstable angina. Thromb Res 1990;60:169.
17. Mielke CH. Measurement of the bleeding time. Thromb Haemost 1984;52:210.
18. Thebault JJ, Blatrix CE, Blanchard JF, Panak E. The interactions of ticlopidine and aspirin in normal subjects. J Int Med Res 1977; 5:405.
19. Conard J, Hanin B, Lecrubier C, Horellou MH, Bousser MG, Samama M. Effects of administration of the association ticlopidine and aspirin on platelet function and hemostatic variables. In: Strano A, ed. International Conference - Platelet Function and Cardiovascular Diseases. Amsterdam: Excerpta Medica, 1984, 108.
20. Lecrubier C, Conard J, Horellou MH, Samama M. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. Agents Actions 1983;13:77.
21. Uchiyama S, Sone R, Nagayama T, Shibagaki Y, Kobayashi I, Maruyama S, Kusakabe K. Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia. Stroke 1989;20:1643.
22. De Caterina R, Sicari R, Bemini W, Lazzerini G, Strata GB, Giannessi D. Benefit/risk profile of combined antiplatelet therapy with ticlopidine and aspirin. Thromb Haemost 1991;5:504.
23. O'Brien JR, Etherington MD, Shuttleworth RD. Ticlopidine - an antiplatelet drug: Effects in human volunteers. Thromb Res 1978; 13:245.
24. David JL, Monfort F, Herion F, Raskinet R. Compared effects of three dose-levels of ticlopidine on platelet function in normal subjects. Thromb Res 1979;14:35.
25. Knudsen JB, Gormsen J. The effect of ticlopidine on platelet function in normal volunteers and in patients with platelet hyperaggregability in vitro. Thromb Res 1979;16:663.
26. Potevin F, Lecompte T, Lecrubier C, Samama M. Administration of ticlopidine impedes ADP-induced activation but does not induce a thrombasthenic state. [Abstract] Thromb Haemost 1987;58:289.
27. Féliste R, Delebassée D, Simon MF, et al. Broad spectrum antiplatelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res 1987;48:403.
28. Jorgensen KA, Dyerberg J, Diesen AS, Stoffersen E. Acetylsalicylic acid, bleeding time and age. Thromb Res 1980;19:799.
29. Jakubowski JA, Stampfer MJ, Vaillancourt R, Deykin D. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol 1985;60:635.
30. Kallmann R, Nieuwenhuis HK, de Groot PG, van Gijn J, Sixma JJ. Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 alpha excretion in healthy subjects. Thromb Res 1987;45:355.
31. Lanza F, Beretz A, Stierlé A, Hanau D, Kubina M, Cazenave JP. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988;255:1276.
32. Panak E, Maffrand JP, Picard-Fraire C, Vallée E, Blanchard J, Roncucci R. Ticlopidine: A promise for the prevention and treatment of thrombosis and its complications. Haemostasis 1983;13:1.
33. Knoll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989;74:1181.
34. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B for the Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501.
35. Bellavance A. Efficacy of ticlopidine and ASA for prevention of reversible cerebrovascular ischemic events. The ticlopidine ASA stroke study. Stroke 1993;10:1452.
36. Barragan P, Sainsous J, Silvestri M, et al. Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting. Cathet Cardiovasc Diagn 1994;32:133.
37. Morice MC, Commeau P, Monassier JP, et al. Coronary stenting without coumadin. Phase II, III, IV, V. Predictors of major complications. [Abstract 1407] XVIIth Congress of the European Society of Cardiology. August, 1995.
38. Van Belle E, McFadden EP, Lablanche JM, Bauters C, Hamon M, Bertrand ME. Two-pronged antiplatelet therapy with aspirin and ticlopidine without systemic anticogulation: an alternative therapeutic strategy after bailout stent implantation. Coronary Artery Dis 1995;6:341.
39. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215.
40. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. New Engl J Med 1996;334:1084.